- Trial Phase
- Phase 2
- Time to Market
- At least 3-5 years — a Phase 3 trial in Parkinson's would need to be designed, enrolled, and completed before any regulatory filing. The drug is still in Phase 2 for all indications.
- Why 5/10
- The next hard catalyst is the ADDRESS-LC (Long COVID) Phase 2 topline data, expected 'late summer 2026' (imminent as of Sep 2026). However, the major binary — the Phase 2 SUNRISE-PD Parkinson's readout — has already passed (Aug 6, 2026). Bezisterim is BioVie's lead asset but the company also has BIV201 for liver disease, so it is not a pure single-asset binary. ImpactScore of 5 reflects an imminent but non-pivotal readout on the lead program at a cash-constrained company.
Watch for the ADDRESS-LC (Long COVID) topline data, expected late summer 2026 — this is the next binary catalyst. Also monitor the ongoing best-efforts S-1 offering: without a minimum, actual proceeds may be far below the ~$22.7M target, accelerating the need for further dilutive financing. The recent insider buying (CEO, CFO, CMO) is a positive signal but does not change the fundamental cash-burn risk.
Price Chart
Executive Summary
NE3107 (bezisterim) is BioVie Inc.'s lead investigational drug — an oral anti-neuroinflammatory agent being developed for Parkinson's disease, Alzheimer's disease, and Long COVID. In August 2026, BioVie announced positive Phase 2 SUNRISE-PD topline results in early Parkinson's (57 patients), meeting prespecified endpoints with statistically significant improvements on motor/non-motor symptoms and favorable biomarker shifts. The stock trades at ~$2.03 with a strong analyst consensus (7 Buy/Strong Buy, mean PT $5.26) and recent insider buying from the CEO, CFO, and CMO. However, BioVie is a pre-revenue clinical-stage company with only $9M cash, a $374M accumulated deficit, an explicit going-concern warning, and serial dilution risk (19 offering filings in 24 months). Short interest has surged to ~14.8% of shares outstanding. The next catalyst is the ADDRESS-LC Long COVID Phase 2 readout, expected imminently.
How It Works
NE3107 (bezisterim) is an oral, small-molecule drug that targets neuroinflammation — a key driver of neurodegenerative diseases. It works by modulating inflammatory signaling pathways in the brain, shifting the balance from pro-inflammatory to anti-inflammatory proteins. In the Phase 2 Parkinson's trial, 283 of 380 measured inflammatory proteins moved in the direction of lower inflammation, and a composite neuroinflammation measure improved significantly versus placebo. It is designed to be a non-hormonal, non-steroidal anti-inflammatory approach to treating diseases like Parkinson's, Alzheimer's, and Long COVID.
Trial Status
Phase 2 SUNRISE-PD trial in early Parkinson's disease (NCT06757010) is COMPLETED — positive topline results announced Aug 6, 2026. The ADDRESS-LC Phase 2 trial in Long COVID is ongoing with topline data expected 'late summer 2026' (imminent). An Alzheimer's program is also in earlier-stage development.
The Two-Sided Case
Upcoming Catalysts
- ADDRESS-LC (Long COVID) Phase 2 topline data — expected late summer 2026 (imminent as of Sep 2026)
- Potential advancement to Phase 3 in Parkinson's disease following positive SUNRISE-PD results
- Closure of the ongoing best-efforts S-1 offering — actual proceeds raised will signal cash runway
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOVIE INC. S-1/A BIVI ·Originating report